SOTYKTU

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Japan, Lithuania, Romania, UK.

Active ingredients

The drug SOTYKTU contains one active pharmaceutical ingredient (API):

1	Deucravacitinib UNII N0A21N6RAU - DEUCRAVACITINIB
	Deucravacitinib selectively inhibits the TYK2 enzyme (TYK2 belongs to the JAK family). TYK2 mediates signalling of interleukin-23 (IL-23), interleukin-12 (IL-12), and type I interferons (IFN), which are naturally occurring cytokines involved in inflammatory and immune responses. Deucravacitinib inhibits the release of proinflammatory cytokines and chemokines.
	Read more about Deucravacitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SOTYKTU Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AF07		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02533030
EE	Ravimiamet	3038150, 3038161, 3038172, 3038183
FI	Lääkealan turvallisuus- ja kehittämiskeskus	573217
FR	Base de données publique des médicaments	69187374
IT	Agenzia del Farmaco	050635010, 050635022, 050635034, 050635046, 050635059, 050635061, 050635073, 050635085
JP	医薬品医療機器総合機構	3999057F1021
LT	Valstybinė vaistų kontrolės tarnyba	1096915, 1096916, 1096917, 1096918, 1096919, 1096920, 1096921, 1096922
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69691001, W69691002
US	FDA, National Drug Code	0003-0895